Target intelligence / Profile preview

Alpha-globin gene (HBA)

Target
HBA
Molecular classification
Other (Structural protein family – globin superfamily; does not fall under conventional druggable target categories like "Enzyme," "Receptor," "Transporter," etc.)
01

Overview

The **alpha-globin gene** refers principally to two nearly identical genes, **HBA1** and **HBA2**, located at the alpha-globin locus on chromosome 16. They encode the **alpha-globin protein**, a critical subunit of hemoglobin. Hemoglobin is the main oxygen-carrying protein in red blood cells, composed of two alpha and two beta subunits[3][4][7][8]. Alpha-globin gene expression is tightly regulated during development and is essential for normal oxygen transport and erythrocyte function. Loss or mutation of these genes leads to a range of **alpha thalassemia syndromes** and other hemoglobinopathies, from silent carrier status to severe, life-threatening anemia[3][5][7]. The gene itself is not a classical pharmacological target (e.g., it is not a receptor or enzyme) but is pivotal in molecular diagnostics and gene therapy research for blood disorders[3][5].

Other names
HBA1HBA2alpha-globinα-globinHemoglobin subunit alphaalpha-globin locus
02

Mechanism of action

Not a direct pharmacological target. Some therapies (e.g., gene editing, hydroxyurea) modulate *globin gene expression* or compensate for its loss but do not bind or inhibit the gene/protein directly[3][5].

03

Biological functions

Oxygen transportHemoglobin assembly and stabilityErythropoiesis (red blood cell development)
04

Disease associations

HemoglobinopathiesAlpha thalassemiaAnemiaOther (rarely implicated as a modifier in beta-thalassemia, sickle cell disease)
05

Safety considerations

Germline manipulation or incomplete understanding of genetic compensation; gene therapies pose generic risks such as off-target effects or immunogenicity.There are no direct pharmacological manipulations[3][5].
06

Interacting drugs

Hydroxyurea (indirect, through fetal hemoglobin induction in related diseases)

1 more in the full profile.

07

Biomarkers

Decreased or abnormal alpha-globin quantified in genetic or hemoglobin analyses as a biomarker for associated diseases (e.g., alpha thalassemia diagnosis by α-globin gene deletion/sequence analysis).

Beyond the preview

Go deeper on Alpha-globin gene (HBA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-globin gene (HBA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call